Lynparza

 

Topic mentions per year

Topic mentions per year

2015-2018
024620152018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing… (More)
Is this relevant?
2016
2016
Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2016
Review
2016
 
Is this relevant?
2016
2016
BACKGROUND Maintenance treatment with the oral poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor olaparib (Lynparza… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Cancer including melanoma may be ''addicted" to double strand break (DSB) repair and targeting this process could sensitize them… (More)
Is this relevant?
Review
2016
Review
2016
Recent years have witnessed a renewed interest in PARP-1 inhibitors as promising anticancer agents with multifaceted functions… (More)
Is this relevant?
Review
2016
Review
2016
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of… (More)
Is this relevant?
Review
2015
Review
2015
Lynparza and its companion diagnostic test, BRACAnalysis were approved by the US FDA in December 2014 for recurrent ovarian… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2015
Review
2015
An underlying hallmark of cancers is their genomic instability, which is associated with a greater propensity to accumulate DNA… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 1
Is this relevant?
2015
2015
In December 2014, on the force Web site, executive director Sue Friedman, heralded a game-changing holiday gift for people with… (More)
Is this relevant?